Wajih Yazbek

Wajih Yazbek is a scientist currently employed at GSK since February 2023, following the acquisition of Affinivax, where Wajih has worked as a Research Associate II since September 2018, focusing on assay development for vaccine-based immunological therapies. Wajih's background includes experience as a Clinical Laboratory Technician at Northeastern University, conducting COVID-19 PCR testing, and as a Research Associate at TGA Sciences, Inc., where responsibilities included sample analysis and client communication. Previous roles also include work as a Clinical Research Technician at Progenika, processing clinical samples for genetic testing, and as a Lab Researcher at the University of Massachusetts, where microbiota identification was a key task. Wajih holds a Master's degree in Biotechnology from Northeastern University and a Bachelor of Science in Biology with a minor in Biotechnology from UMass Boston.